Search hospitals > New Jersey > New Brunswick
Rutgers Cancer Institute of New Jersey
Claim this profileNew Brunswick, New Jersey 08901
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Tumors
Conducts research for Leukemia
Conducts research for Lymphoma
1005 reported clinical trials
65 medical researchers
Summary
Rutgers Cancer Institute of New Jersey is a medical facility located in New Brunswick, New Jersey. This center is recognized for care of Cancer, Breast Cancer, Tumors, Leukemia, Lymphoma and other specialties. Rutgers Cancer Institute of New Jersey is involved with conducting 1,005 clinical trials across 727 conditions. There are 65 research doctors associated with this hospital, such as Sanjay Goel, Howard S. Hochster, Janice M. Mehnert, and Missak Haigentz, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
HER2 negative
Stage III
Top PIs
Sanjay GoelMontefiore Medical Center4 years of reported clinical research
Expert in Solid Tumors
Expert in Tumors
22 reported clinical trials
31 drugs studied
Howard S. HochsterRutgers Cancer Institute of New Jersey4 years of reported clinical research
Expert in Colorectal Cancer
Studies Colon Cancer
17 reported clinical trials
37 drugs studied
Janice M. MehnertLaura and Isaac Perlmutter Cancer Center at NYU Langone3 years of reported clinical research
Studies Cancer
Studies Tumors
16 reported clinical trials
19 drugs studied
Missak Haigentz, MDRutgers Cancer Institute of New Jersey3 years of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
14 reported clinical trials
23 drugs studied
Clinical Trials running at Rutgers Cancer Institute of New Jersey
Breast Cancer
Prostate Cancer
Non-Small Cell Lung Cancer
Cancer
Lymphoma
Lung Cancer
Bladder Cancer
Osteosarcoma
Brain Tumor
Germ Cell Tumors
Sacituzumab Govitecan
for Triple-Negative Breast Cancer
This trial is testing a drug called sacituzumab govitecan-hziy, which targets and kills cancer cells. It focuses on patients with advanced triple-negative breast cancer who have limited treatment options. The drug works by attaching to cancer cells and releasing a substance that kills them. Sacituzumab govitecan-hziy is an FDA-approved treatment for metastatic triple-negative breast cancer, especially for patients who have already tried other treatments.
Recruiting4 awards Phase 3
Sacituzumab Govitecan + Pembrolizumab
for Triple-Negative Breast Cancer
This trial compares the effectiveness of a combination of two drugs, SG and pembrolizumab, in patients with advanced triple-negative breast cancer. SG targets and kills cancer cells with chemotherapy, while pembrolizumab helps the immune system attack the cancer. Pembrolizumab has been shown to improve survival in various cancers, including triple-negative breast cancer, when used alone or in combination with other treatments.
Recruiting4 awards Phase 3
Giredestrant + Hormone Therapy
for Early-Stage Breast Cancer
This trial is testing giredestrant, a medication given after initial treatment to prevent breast cancer from returning. It focuses on patients with a specific type of early-stage breast cancer that is hormone-driven and at higher risk of recurrence. Giredestrant works by blocking the hormone estrogen from helping cancer cells grow. Giredestrant has shown promise in previous studies.
Recruiting2 awards Phase 311 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Rutgers Cancer Institute of New Jersey?
Rutgers Cancer Institute of New Jersey is a medical facility located in New Brunswick, New Jersey. This center is recognized for care of Cancer, Breast Cancer, Tumors, Leukemia, Lymphoma and other specialties. Rutgers Cancer Institute of New Jersey is involved with conducting 1,005 clinical trials across 727 conditions. There are 65 research doctors associated with this hospital, such as Sanjay Goel, Howard S. Hochster, Janice M. Mehnert, and Missak Haigentz, MD.
Where is Rutgers Cancer Institute of New Jersey located?
**Rutgers Cancer Institute of New Jersey**
- **Address:** 195 Little Albany Street, New Brunswick, NJ.
- **Transportation:** Accessible by car, bus (810, 811, 814, 815, 818), and train (New Jersey Transit/Northeast Corridor Line).
Who should I call to ask about financial aid or insurance network?
**Financial Assistance and Support at Rutgers Cancer Institute of New Jersey:**
- For financial assistance, contact the New Patient Access Center at 732-235-2465.
- For insurance inquiries, visit the Rutgers Cancer Institute of New Jersey's website or call 732-235-2465.
- Additional resources include CancerCare for financial aid related to cancer treatment costs and the Cancer Support Community for support, education, and hope.
What insurance does Rutgers Cancer Institute of New Jersey accept?
The Rutgers Cancer Institute of New Jersey accepts a wide range of insurance plans, including CHN PPO, Cigna, First MCO/ActiveCare, Group Health Incorporated (GHI), Health Care Payers Coalition, Horizon BCBS, and many others. Patients are encouraged to contact their insurance company to verify coverage details and financial responsibilities. Financial counselors at the Institute are available to assist with maximizing benefits; for consultations, contact 732-235-8067.
What awards or recognition has Rutgers Cancer Institute of New Jersey received?
Rutgers Cancer Institute of New Jersey, the state's only National Cancer Institute (NCI)-designated Comprehensive Cancer Center, underscores its commitment to research, treatment, prevention, and care. It has received a transformative investment of $750 million for the construction of New Jersey's first free-standing cancer hospital, the Jack and Sheryl Morris Cancer Center in New Brunswick. This funding and recognition for research and care solidify its leading position in cancer treatment and research.